secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2025-08-04T23:59:59+00:00
Accession:  0001447362-25-000096
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences Q2 revenue $86.2M, raises FY2025 guidance; core test volumes up 33% YoY
--------------------------------------------------------------------------------

- Q2 revenue $86.2M (vs $87.0M); adjusted revenue $86.2M. Core tests (DecisionDx-Melanoma, TissueCypher) volumes up 33% YoY.
- TissueCypher test reports nearly doubled to 9,170 (from 4,782); DecisionDx-Melanoma up 4% to 9,981.
- Raising FY2025 total revenue guidance to $310-320M from $287-297M, citing strong core test performance.
- Net income $4.5M ($0.16 diluted EPS) vs $8.9M ($0.32) YoY; adjusted EBITDA $10.4M vs $21.5M.
- FDA Breakthrough Device designation for DecisionDx-Melanoma; closed Previse acquisition and SciBase collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000144736225000096/0001447362-25-000096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000144736225000096/cstl-20250804.htm
  HTML page:      https://secwatch.observer/filing/0001447362-25-000096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer